<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1871">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136807</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0172</org_study_id>
    <secondary_id>NCI-2021-11118</secondary_id>
    <secondary_id>2016-0172</secondary_id>
    <nct_id>NCT05136807</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies</brief_title>
  <official_title>Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the quality of life in patients with monoclonal gammopathy of unknown&#xD;
      significance and smoldering multiple myeloma. Collecting quality of life information from&#xD;
      patients may help doctors learn more about the most common symptoms and concerns patients&#xD;
      with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown&#xD;
      significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM&#xD;
      already participating in clinical trials at MD Anderson Cancer Center.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Identify the most common symptoms/patients concerns to evaluate future interventions for&#xD;
      treatment/prevention in this population.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6&#xD;
      months for patients participating in an observational study or every month for patients&#xD;
      participating in a treatment study for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Patients complete quality of life questionnaires over 10-15 minutes at baseline.&#xD;
Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Patients complete quality of life questionnaires every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.&#xD;
Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Monoclonal Gammopathy of Undetermined Significance</condition>
  <condition>Smoldering Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Observational (quality of life questionnaire)</arm_group_label>
    <description>Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (quality of life questionnaire)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (quality of life questionnaire)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with monoclonal gammopathy of unknown significance or smoldering multiple myeloma&#xD;
        at MD Anderson Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either monoclonal gammopathy of unknown significance age &gt;= 18 years&#xD;
             old.&#xD;
&#xD;
               -  Both criteria must be met:&#xD;
&#xD;
                    -  Serum monoclonal protein &lt; 3 g/dL or urinary monoclonal protein &lt; 500 mg per&#xD;
                       24 hours and clonal bone marrow plasma cells &lt; 10%&#xD;
&#xD;
                    -  Absence of myeloma defining events or amyloidosis&#xD;
&#xD;
          -  OR Patients with smoldering multiple myeloma age &gt;= 18 years old.&#xD;
&#xD;
               -  Both criteria must be met:&#xD;
&#xD;
                    -  Serum monoclonal protein &gt;= 3 g/dL or urinary monoclonal protein &gt;= 500 mg&#xD;
                       per 24 hours and/or clonal bone marrow plasma cells 10-60%&#xD;
&#xD;
                    -  Absence of myeloma defining events or amyloidosis&#xD;
&#xD;
          -  Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer&#xD;
             Center, including protocols PA15-0575 (NCT02726750) (Prospective observational study&#xD;
             of clinical and genomic predictors of progression to myeloma in asymptomatic&#xD;
             monoclonal gammopathies); 2015-0148 (Phase II single arm trial of Isatuximab in&#xD;
             patients with intermediate and high risk smoldering multiple myeloma); and 2015-0371&#xD;
             (NCT02603887) (Pilot single arm, single center, open label trial of Pembrolizumab in&#xD;
             patients with intermediate and high risk smoldering multiple myeloma) and any future&#xD;
             clinical trials for MGUS and/or SMM that open at MD Anderson Cancer Center.&#xD;
&#xD;
          -  Only patients who are English or Spanish speaking are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of myeloma defining events or biomarkers of malignancy due to underlying&#xD;
             plasma cell proliferative disorder meeting at least one of the following&#xD;
&#xD;
               -  Hypercalcemia: serum calcium &gt; 0.25 mmol/L (&gt; 1 mg/dL) higher than the upper&#xD;
                  limit of normal or &gt; 2.75 mmol/L (&gt; 11 mg/dL)&#xD;
&#xD;
               -  Renal Insufficiency: creatinine clearance &lt; 40 ml/min or serum creatinine &gt; 2&#xD;
                  mg/dL&#xD;
&#xD;
               -  Anemia: hemoglobin value &lt; 10 g/dL or 2 g/dL &lt; normal reference&#xD;
&#xD;
               -  Bone lesions: one or more osteolytic lesions on skeletal radiography,&#xD;
                  computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron&#xD;
                  emission tomography CT (PET-CT).&#xD;
&#xD;
               -  Clonal bone marrow plasma cell percentage &gt;= 60%&#xD;
&#xD;
               -  Involved: uninvolved serum free light chain ratio &gt;= 100 measured by Freelite&#xD;
                  assay (The Binding Site Group, Birmingham, United Kingdom [UK])&#xD;
&#xD;
               -  &gt;1 focal lesions on magnetic resonance imaging (MRI) studies, if the patient has&#xD;
                  an MRI done per eligibility criteria (each focal lesion must be 5 mm or more in&#xD;
                  size)&#xD;
&#xD;
          -  Plasma cell leukemia.&#xD;
&#xD;
          -  Presence of cognitive impairment or delirium as determined by the primary clinician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabet E Manasanch</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Huang</last_name>
    <phone>713-745-9901</phone>
    <email>mhuang3@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Huang</last_name>
      <phone>713-745-9901</phone>
      <email>mhuang3@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elisabet E. Manasanch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

